Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 3/20 | 0.64 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 7/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.56 |
| ▸ | CCR2 | P41597 | 4/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4579190 | 0.92 | CCR3 (0.62) | CCR3GRIN2BROCK2ROCK1CCR2 | |
| SCHEMBL4576718 | 0.90 | GRIN2B (0.60) | CCR3GRIN2BROCK2ROCK1CCR2 | |
| SCHEMBL4577575 | 0.82 | GRIN2B (0.55) | CCR3GRIN2BGRIN1 | |
| SCHEMBL4579336 | 0.81 | CCR3 (0.74) | CCR3GRIN2BROCK2ROCK1CCR2 | |
| SCHEMBL4580802 | 0.81 | GRIN1 (0.73) | GRIN2BGRIN1 | |
| SCHEMBL27608834 | 0.80 | FAAH (0.52) | GRIN2BGRIN1 | |
| Hydrochloric Acid SCHEMBL4578850 | 0.80 | GRIN1 (0.71) | GRIN2BGRIN1 | |
| SCHEMBL4577310 | 0.79 | FAAH (0.68) | GRIN2BGRIN1 | |
| SCHEMBL6702434 | 0.78 | CCR3 (1.00) | CCR3GRIN2BROCK2ROCK1CCR2 | |
| SCHEMBL4578882 | 0.78 | GRIN1 (0.74) | GRIN2BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435744-B2 | Piperidine derivatives as NMDA receptor antagonists | GEDEON RICHTER VEGYESZETI GYAR RT (HU) | 2008-10-14 | — | — | US | disclosed |
| EP-1409477-B1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2008-09-17 | — | — | EP | disclosed |
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | UCB Biopharma SRL (BE) | 2004-08-12 | — | — | US | disclosed |
| EP-1409477-A1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003010159-A1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | GRIN1, GRIN2D, GRIN2C | CCR3 672/4885GRIN2B 7/4885ROCK2 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.